This phenomenon is being utilized clinically in CR-PCa patients by withdrawing anti-androgens from the ADT treatment regimen [26], a strategy that has been shown to decrease PSA and increase progression-free survival [101]. Here, KLK3 is linked to posterior cortical atrophy.